Seviteronel
Seviteronel
Seviteronel (pronounced as Se-vi-te-ro-nel) is a nonsteroidal CYP17 inhibitor that is currently under investigation for its potential use in the treatment of prostate cancer and breast cancer. It is being developed by Innocrin Pharmaceuticals.
Etymology
The term "Seviteronel" is a coined name for this specific drug compound. The name does not have a known etymology.
Mechanism of Action
Seviteronel works by inhibiting the enzyme CYP17A1, which is involved in the production of androgens and estrogens. By blocking this enzyme, Seviteronel can potentially slow the growth of hormone-dependent cancers such as prostate and breast cancer.
Clinical Trials
Seviteronel has been tested in several clinical trials for its efficacy and safety in treating prostate and breast cancer. The results of these trials are still pending.
Related Terms
- CYP17A1: An enzyme that is involved in the production of androgens and estrogens.
- Prostate Cancer: A type of cancer that occurs in the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm.
- Breast Cancer: A type of cancer that forms in the cells of the breasts.
- Clinical Trials: Research studies that involve people. They test whether drugs, medical treatments, or devices are safe and effective.
External links
- Medical encyclopedia article on Seviteronel
- Wikipedia's article - Seviteronel
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski